Loading
PROCEPT BioRobotics Corp Stock: price and insider trades · United States
1 insider bought €432k of shares over the last 90 days, the latest filed 10 Aug 2026.
PROCEPT BioRobotics Corp: what insiders have been doing
This page follows insider dealings at PROCEPT BioRobotics Corp as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. In the past year (18 October 2025 to 18 October 2026), 29 filings came from 13 insiders.
The record shows 2 purchases on the open market worth €3.5M, made by 2 insiders, against 7 sales worth €180k by 3 insiders. Netting one side against the other leaves €3.4M of net buying. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The buyers include 1 senior executive and 1 chief executive. At €3.1M, the purchase published on 9 March 2026 by Desai Antal Rohit is the largest of the period.
With 29 filings in twelve months, the company is more active than the median of 19 filings across the 5,808 companies we follow on the same exchange. Looking back to 2021, when coverage begins, insiders filed 5 purchases and 45 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 308.1 m USD and net income of -95.6 m USD.
The latest purchase dates back some time: it was published 68 days ago, on 10 August 2026. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
175
Thresholds
n/a
Buy Volume
€4M
5 ops. · all time
Sell Volume
€48M
45 ops. · all time
Who traded when
BuySaleAlaleh Nouri6 sales
Zadno Reza6 sales
Kevin Waters4 sales
Antal Rohit Desai1 buy2 sales
Shiblaq Hisham2 sales
Barry L. Templin1 sale
+2 other insiders
Since the insiders bought
- -16.6%Entry US$22.89 · Close 13 Oct 2026 US$19.10
- +17.3%Entry US$24.17 · Close at T+90 US$28.35
- -49.3%Entry US$41.59 · Close at T+365 US$21.09
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate PROCEPT BioRobotics Corp Hold (neutral), based on 12 analysts. Average price target: US$22.33.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,812 of 24,148 companies
25.8
score / 100
Value19
Quality33
FCF yld-5.8%
Earn yld-9.5%
EV/EBITDA·
ROE-30%
Gross mgn64%
Net mgn-31%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$19.10
Analyst consensus
12 analystsHold
US$16.00Target US$22.33(+17%)US$30.00
Income statement
RevenueUS$308.1M
Gross profitUS$196.2M64% margin
EBITDA-US$85.4M-28% margin
Net income-US$95.6M-32.5% margin
Valuation
PER (forward)-16.3x
P/Book3.2x
Beta0.92
Balance sheet & cash
Market capUS$1.1B
Total debtUS$78.5M
Free Cash Flow-US$58.3M
Debt / Equity23%
Profitability & ownership
ROE-30.2%
ROA-14.8%
% insiders3.5%
% institutions100.5%
Last declaration on 5 October 2026
Declarations175 total
7,727 shares0Common StockSEC:0001628280-26-064925:0
297 shares@ US$20.9530.0006% mcap0.2% of flowCommon StockSEC:0001599418-26-000002:0
373 shares@ US$20.9530.0007% mcap30.2% of flowCommon StockSEC:0001588978-26-000032:0
373 shares@ US$20.9530.0007% mcap0.3% of flowCommon StockSEC:0001653771-26-000002:0
297 shares@ US$20.95320.0006% mcap0.2% of flowCommonSEC144:0001959173-26-006829
373 shares@ US$20.95320.0007% mcap30.2% of flowCommonSEC144:0001959173-26-006828
373 shares@ US$20.95320.0007% mcap0.3% of flowCommonSEC144:0001959173-26-006827
22,965 shares0Common StockSEC:0001628280-26-057165:0
23,622 shares0Common StockSEC:0001628280-26-057156:0
29,527 shares0Common StockSEC:0001628280-26-057160:0
26,246 shares0Common StockSEC:0001628280-26-057163:0
23,900 shares@ US$20.850.047% mcap100.0% of flowCommon StockSEC:0001628280-26-054970:0
Canonical exit: 5 Nov 2026 (T+90)
3,315 sharesCommon StockSEC:0001628280-26-042277:0
3,315 sharesCommon StockSEC:0001628280-26-042273:0
3,315 sharesCommon StockSEC:0001628280-26-042270:0
357 shares@ US$28.4790.0008% mcap0.4% of flowCommonSEC144:0001959173-26-004442
285 shares@ US$28.4790.0007% mcap0.3% of flowCommonSEC144:0001959173-26-004447
358 shares@ US$28.4790.0008% mcap39.7% of flowCommonSEC144:0001959173-26-004435
3,031 shares@ US$25.81933.0% of flowCommon StockSEC:0001628280-26-019900:0
706 shares@ US$28.15320.7% of flowCommon StockSEC:0001628280-26-019830:0
304 shares@ US$28.15320.3% of flowCommon StockSEC:0001628280-26-019833:0
3,098 shares@ US$25.60373.0% of flowCommon StockSEC:0001628280-26-017218:0
43,811 shares0Common StockSEC:0001628280-26-016153:0
127,783 shares0Common StockSEC:0001628280-26-016156:0
47,462 shares0Common StockSEC:0001628280-26-016151:0
25 of 175 declarations
About PROCEPT BioRobotics Corp
PROCEPT BioRobotics Corp. (ticker: PRCT) is a U.S.-listed medical device company traded on the NASDAQ market in the United States. The company is a focused player in surgical robotics, with a narrow but differentiated strategic emphasis on urology and, in particular, the treatment of benign prostatic hyperplasia (BPH), one of the most common prostate conditions in men. PROCEPT was incorporated in 2007 and is headquartered in San Jose, California, a location that reinforces its Silicon Valley identity and access to engineering, software, and medical-technology talent. ([ir.procept-biorobotics.com](https://ir.procept-biorobotics.com/investor-relations?utm_source=openai))
At the center of the business is the AQUABEAM Robotic System and its Aquablation therapy procedure. Aquablation is a minimally invasive, image-guided treatment that combines real-time ultrasound, cystoscopy, and robotic execution to remove obstructive prostate tissue in a controlled manner. PROCEPT’s commercial proposition is built around a clinically distinct value chain: it is not a broad surgical robotics platform company, but rather a category specialist focused on a single high-value urology indication. The company highlights clinical durability, symptom relief, and preservation of sexual function and continence as key differentiators versus more traditional surgical approaches. ([ir.procept-biorobotics.com](https://ir.procept-biorobotics.com/node/8641/pdf))
Read moreShow less
A major product milestone was the FDA clearance and U.S. launch of HYDROS, the next-generation AI-powered robotic system for Aquablation therapy. According to company materials, HYDROS adds AI-assisted treatment planning, enhanced image guidance, and a streamlined workflow intended to improve operating-room efficiency and surgeon experience. PROCEPT describes HYDROS as the evolution of its robotic platform and a basis for broader adoption in the U.S. market. The company also notes an expanding installed base of robotic systems in the United States, supporting recurring procedure growth over time. ([ir.procept-biorobotics.com](https://ir.procept-biorobotics.com/node/8641/pdf))
From a competitive standpoint, PROCEPT occupies a specialized niche in a market where larger surgical robotics franchises tend to focus on broader procedural categories. That specialization can be an advantage because it allows the company to build a strong clinical narrative, concentrate sales and training efforts, and target a sizable unmet need in BPH treatment. At the same time, the investment case remains dependent on adoption rates, reimbursement dynamics, physician training, and hospital capital purchasing decisions, which are all important for a commercial-stage medtech company. ([procept-biorobotics.com](https://www.procept-biorobotics.com/about-us?utm_source=openai))
Recent developments have been encouraging. In May 2026, PROCEPT said that updated American Urological Association guidelines strengthened the recommendation for Aquablation therapy, an important validation for the procedure’s clinical profile and market position. In its first-quarter 2026 results, the company reported revenue of $83.132 million, reflecting continued top-line momentum. PROCEPT has also remained active on the investor-conference circuit, underscoring management’s focus on visibility and capital-markets engagement. ([ir.procept-biorobotics.com](https://ir.procept-biorobotics.com/))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
